Whitney W Stevens1, Anju T Peters1, Bruce K Tan2, Aiko I Klingler1, Julie A Poposki1, Kathryn E Hulse1, Leslie C Grammer1, Kevin C Welch2, Stephanie S Smith2, David B Conley2, Robert C Kern3, Robert P Schleimer3, Atsushi Kato4. 1. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. 2. Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Ill. 3. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Ill. 4. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: a-kato@northwestern.edu.
Abstract
BACKGROUND: Chronic rhinosinusitis (CRS) is a heterogeneous disease characterized by mucosal inflammation in the nose and paranasal sinuses. Inflammation in CRS is also heterogeneous and is mainly characterized by type 2 (T2) inflammation, but subsets of patients show type 1 (T1) and type 3 (T3) inflammation. Whether inflammatory endotypes are associated with clinical phenotypes has yet to be explored in detail. OBJECTIVE: To identify associations between inflammatory endotypes and clinical presentations in CRS. METHODS: We compared 121 patients with nonpolypoid CRS (CRSsNP) and 134 patients with polypoid CRS (CRSwNP) and identified inflammatory endotypes using markers including IFN-γ (T1), eosinophil cationic protein (T2), Charcot-Leyden crystal galectin (T2), and IL-17A (T3). We collected clinical parameters from medical and surgical records and examined whether there were any associations between endotype and clinical features. RESULTS: The presence of nasal polyps, asthma comorbidity, smell loss, and allergic mucin was significantly associated with the presence of T2 endotype in all patients with CRS. The T1 endotype was significantly more common in females, and the presence of pus was significantly associated with T3 endotype in all patients with CRS. We further analyzed these associations in CRSsNP and CRSwNP separately and found that smell loss was still associated with T2 endotype and pus with the T3 endotype in both CRSsNP and CRSwNP. Importantly, patients with CRS with T2 and T3 mixed endotype tended to have clinical presentations shared by both T2 and T3 endotypes. CONCLUSIONS: Clinical presentations are directly associated with inflammatory endotypes in CRS. Identification of inflammatory endotypes may allow for more precise and personalized medical treatments in CRS.
BACKGROUND:Chronic rhinosinusitis (CRS) is a heterogeneous disease characterized by mucosal inflammation in the nose and paranasal sinuses. Inflammation in CRS is also heterogeneous and is mainly characterized by type 2 (T2) inflammation, but subsets of patients show type 1 (T1) and type 3 (T3) inflammation. Whether inflammatory endotypes are associated with clinical phenotypes has yet to be explored in detail. OBJECTIVE: To identify associations between inflammatory endotypes and clinical presentations in CRS. METHODS: We compared 121 patients with nonpolypoid CRS (CRSsNP) and 134 patients with polypoid CRS (CRSwNP) and identified inflammatory endotypes using markers including IFN-γ (T1), eosinophil cationic protein (T2), Charcot-Leyden crystal galectin (T2), and IL-17A (T3). We collected clinical parameters from medical and surgical records and examined whether there were any associations between endotype and clinical features. RESULTS: The presence of nasal polyps, asthma comorbidity, smell loss, and allergicmucin was significantly associated with the presence of T2 endotype in all patients with CRS. The T1 endotype was significantly more common in females, and the presence of pus was significantly associated with T3 endotype in all patients with CRS. We further analyzed these associations in CRSsNP and CRSwNP separately and found that smell loss was still associated with T2 endotype and pus with the T3 endotype in both CRSsNP and CRSwNP. Importantly, patients with CRS with T2 and T3 mixed endotype tended to have clinical presentations shared by both T2 and T3 endotypes. CONCLUSIONS: Clinical presentations are directly associated with inflammatory endotypes in CRS. Identification of inflammatory endotypes may allow for more precise and personalized medical treatments in CRS.
Authors: Whitney W Stevens; Christopher J Ocampo; Sergejs Berdnikovs; Masafumi Sakashita; Mahboobeh Mahdavinia; Lydia Suh; Tetsuji Takabayashi; James E Norton; Kathryn E Hulse; David B Conley; Rakesh K Chandra; Bruce K Tan; Anju T Peters; Leslie C Grammer; Atsushi Kato; Kathleen E Harris; Roderick G Carter; Shigeharu Fujieda; Robert C Kern; Robert P Schleimer Journal: Am J Respir Crit Care Med Date: 2015-09-15 Impact factor: 21.405
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinol Suppl Date: 2012-03
Authors: A G Hirsch; X S Yan; A S Sundaresan; B K Tan; R P Schleimer; R C Kern; T L Kennedy; J S Greene; B S Schwartz Journal: Allergy Date: 2015-09-25 Impact factor: 13.146
Authors: Stephanie Shintani Smith; Charlesnika T Evans; Bruce K Tan; Rakesh K Chandra; Sean B Smith; Robert C Kern Journal: J Allergy Clin Immunol Date: 2013-08-26 Impact factor: 10.793
Authors: Loreto Abusleme; Patricia I Diaz; Alexandra F Freeman; Teresa Greenwell-Wild; Laurie Brenchley; Jigar V Desai; Weng-Ian Ng; Steven M Holland; Michail S Lionakis; Julia A Segre; Heidi H Kong; Niki M Moutsopoulos Journal: JCI Insight Date: 2018-09-06
Authors: Chih-Hsi Scott Kuo; Stelios Pavlidis; Matthew Loza; Fred Baribaud; Anthony Rowe; Iaonnis Pandis; Ana Sousa; Julie Corfield; Ratko Djukanovic; Rene Lutter; Peter J Sterk; Charles Auffray; Yike Guo; Ian M Adcock; Kian Fan Chung Journal: Eur Respir J Date: 2017-02-08 Impact factor: 16.671
Authors: Whitney W Stevens; Anju T Peters; Lydia Suh; James E Norton; Robert C Kern; David B Conley; Rakesh K Chandra; Bruce K Tan; Leslie C Grammer; Kathleen E Harris; Roderick G Carter; Atsushi Kato; Margrit Urbanek; Robert P Schleimer; Kathryn E Hulse Journal: Immun Inflamm Dis Date: 2015-02-12
Authors: Karina Bayer; Selmir Hamidovic; Faris F Brkic; Gerold Besser; Christian A Mueller; David T Liu Journal: Eur Arch Otorhinolaryngol Date: 2022-06-23 Impact factor: 2.503
Authors: William Eschenbacher; Matthew Straesser; Alice Knoeddler; Rung-Chi Li; Larry Borish Journal: Immunol Allergy Clin North Am Date: 2020-09-09 Impact factor: 3.479
Authors: Aiko I Klingler; Whitney W Stevens; Bruce K Tan; Anju T Peters; Julie A Poposki; Leslie C Grammer; Kevin C Welch; Stephanie S Smith; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato Journal: J Allergy Clin Immunol Date: 2020-12-14 Impact factor: 10.793
Authors: Robert Naclerio; Fuad Baroody; Claus Bachert; Benjamin Bleier; Larry Borish; Erica Brittain; Geoffrey Chupp; Anat Fisher; Wytske Fokkens; Philippe Gevaert; David Kennedy; Jean Kim; Tanya M Laidlaw; Jake J Lee; Jay F Piccirillo; Jayant M Pinto; Lauren T Roland; Robert P Schleimer; Rodney J Schlosser; Julie M Schwaninger; Timothy L Smith; Bruce K Tan; Ming Tan; Elina Toskala; Sally Wenzel; Alkis Togias Journal: J Allergy Clin Immunol Pract Date: 2020-03-04
Authors: Elizabeth A Sell; Jorge F Ortiz-Carpena; De'Broski R Herbert; Noam A Cohen Journal: Ann Allergy Asthma Immunol Date: 2020-10-26 Impact factor: 6.347